A clinical deep-dive on how slowing titration, pausing, stepping down, or microdosing AndroGel can reduce secondary testosterone transfer risk to women and children, including real protocols and escalation criteria.
A deep-dive into the clinical implications of the STEP-1 Extension trial: which prescribing patterns shifted, which guidelines updated, and what the weight-regain data means for patients who differ from the trial population.
A deep-dive into the economic modeling, payer-coverage implications, and patient-level value calculations that flow from the STEP-8 head-to-head trial of semaglutide 2.4 mg versus liraglutide 3.0 mg.
A guide to sirolimus pharmacogenomics, dosing, and safety considerations specific to Hispanic and Latino patients, covering CYP3A5 variants, diabetes risk, dyslipidemia, and ethnicity-stratified trial data.
A clinical-grade breakdown of why tirzepatide triggers local subcutaneous histamine release and mechanical tissue responses, with actionable management steps for patients and prescribers.
A clinical deep-dive on how slowing titration, pausing, stepping down, and microdosing AndroGel can resolve gynecomastia caused by excess aromatization. Real protocols, when each works, and when to escalate.
A deep methodological critique of the SELECT trial (semaglutide 2.4 mg, NEJM 2023): enrollment biases, follow-up gaps, statistical caveats, COI concerns, and what post-publication commentary revealed.
A guide to mixed amphetamine salts (Adderall XR) dosing when GFR is reduced, covering pharmacokinetics, dose adjustment protocols, monitoring, and safety evidence.
A clinician-level guide to the alendronate pre-surgery hold window: when to pause Fosamax, how long bone binding lasts, fracture risk versus surgical risk, and current guideline consensus.
A clinical overview of BPC-157 pentadecapeptide in autoimmune disease contexts, covering mechanisms, evidence, risks, and prescribing considerations for 2024.
A critical, data-driven look at Noom's subscription pricing from 2016 to 2024, GLP-1 add-on costs, complaint patterns, and whether the platform delivers clinically meaningful weight loss.
Find out whether Humana covers Vyleesi (bremelanotide) for HSDD, what prior-authorization criteria apply, how formulary tiers work, and exactly how to appeal a denial in 2024.
A clinical comparison of Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide 3 mg) covering weight-loss efficacy, dosing, side-effect profiles, insurance coverage, and out-of-pocket cost in 2024.
A clinical comparison of Zepbound (tirzepatide) and Ozempic (semaglutide) covering weight loss efficacy, cost, insurance access, and how to choose between them in 2024.
A head-to-head clinical comparison of liraglutide 3 mg (Saxenda) and dulaglutide (Trulicity) for long-term weight loss and glycemic durability, with trial data, real-world evidence, and switching guidance.
A clinical head-to-head of liraglutide 3 mg (Saxenda) and dulaglutide (Trulicity) for weight loss and glycemic control, including a step-by-step switching protocol when one agent stops working.
A look at emerging OSA research, including tirzepatide's FDA-approved role, positive airway pressure, endotypes, devices, and diagnostic advances.
From hormone therapy timing to cardiovascular risk, bioidentical hormones, and testosterone use in women, this HealthRX.com clinical review covers the active controversies shaping menopause care in 2024.
A complete guide to Aetna (CVS Health) Trulicity coverage, prior authorization criteria, step therapy requirements, formulary tier, appeal steps, and cost-saving options for dulaglutide in 2024.
A detailed guide to Kaiser Permanente's Trulicity formulary status, prior authorization requirements, step-therapy rules, appeal process, and cost options for dulaglutide in 2024.
Complete clinical guide to estradiol transdermal dosing when liver function is compromised. Covers pharmacokinetics, patch advantages over oral estradiol, dose selection by Child-Pugh class, monitoring parameters, and safety data from WHI and other primary sources.
A complete guide to Kaiser Permanente formulary status, prior authorization requirements, step therapy, and appeal options for the estradiol transdermal patch in 2024.
A clinical and practical guide to Blue Cross Blue Shield Federated coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, appeal strategies, and cost options for 2024.
A rigorous side-by-side synthesis of four major GLP-1 receptor agonist cardiovascular outcomes trials, comparing MACE reductions, mortality signals, stroke vs. MI effects, and the question of whether benefits extend beyond type 2 diabetes.
Semaglutide 2.4mg produced 10-17% weight loss across five STEP trials, outperforming liraglutide by about 6 points at 68 weeks. See the full data comparison.
A complete clinical breakdown of the SELECT trial, design, results, patient population, and what the 20% MACE reduction means for prescribing semaglutide 2.4 mg in cardiovascular-risk patients without diabetes.
A deep clinical breakdown of the STEP 3 trial, comparing semaglutide 2.4 mg plus intensive behavioral therapy to placebo, with full context from STEP 1, 2, 5, and 8.
A explanation of how tirzepatide (Mounjaro) works, covering its dual GIP/GLP-1 mechanism, clinical trial results, dosing, side effects, and how it compares to other GLP-1 medications.
Saxenda® (liraglutide 3.0 mg) is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and lowers body weight. Learn the full mechanism, dosing schedule, expected results, and who qualifies.
A practical, evidence-informed look at eating strategies that support tolerability and weight outcomes on Saxenda (liraglutide 3.0 mg). Pending qualified medical review.
A guide to the foods that worsen nausea, slow weight loss, and increase GI side effects on Trulicity (dulaglutide), with specific dietary strategies backed by clinical trial data.
A detailed clinical and coverage guide to Saxenda (liraglutide 3 mg) under Blue Cross Blue Shield of Massachusetts plans, including prior authorization steps, appeal strategies, and cost alternatives.
Calibrate requires coaching as a core part of its GLP-1 weight-loss program. Learn what that means clinically, what the research says about behavioral support alongside medication, and how to get the most from the program.
Calibrate is not a pharmacy. Learn exactly how Calibrate prescribes GLP-1 medications, which pharmacies fill those prescriptions, what you pay, and how the model compares to direct telehealth pharmacy programs.
A complete, clinically grounded walkthrough of your first Allara Health visit, from intake paperwork and lab work to diagnosis, treatment planning, and follow-up. Written by the HealthRX.com medical team.
A comprehensive analysis of inclisiran (Leqvio) safety signals, FDA actions, post-market surveillance data, mechanism of action, and clinical trial evidence from ORION-10 and ORION-11.
A clinical guide to Cigna's isotretinoin coverage: formulary tier, prior authorization criteria, step therapy requirements, appeal strategies, and real out-of-pocket costs for 2024.
Isotretinoin is not a controlled substance but is prescription-only with mandatory pregnancy-prevention programs like iPLEDGE, PPP, and Healthy Skin worldwide.
A detailed guide to UnitedHealthcare coverage, prior authorization requirements, formulary tier, step therapy, and appeal strategies for isotretinoin (Accutane) in 2024.
Dayvigo (lemborexant) is not approved by the UK's MHRA or EU's EMA as of mid-2024, though it holds FDA and Health Canada approval. See full status details.
Everything you need to know about traveling with GHK-Cu copper tripeptide peptide therapy: how to store vials in transit, manage airport security, maintain your injection schedule across time zones, and protect skin formulations from heat and humidity.
A clinical and coverage guide to liraglutide on Kaiser Permanente plans: formulary tier, prior authorization criteria, step-therapy requirements, appeal pathways, and cost options for 2024.
A guide to vitamin E dosing in NASH (now called MASLD/MASH), covering the PIVENS trial dose, who qualifies, risks of high-dose tocopherol, and where resmetirom fits in the 2024 treatment landscape.
A detailed guide to BCBS Arizona metformin coverage, formulary tiers, prior authorization, cost-saving strategies, and the clinical evidence behind metformin prescribing in 2024.
A guide to Humana's coverage policies, prior authorization requirements, formulary status, and appeal pathways for low-dose naltrexone (LDN) in 2024.
A guide to Humana's coverage rules, prior authorization criteria, formulary tiers, step-therapy requirements, and appeal pathways for oral micronized progesterone (Prometrium).
A guide to AOD-9604's federal and Arizona-specific legal status, compounding pharmacy pathways, prescription requirements, and what patients need to know before seeking access in 2024.
A guide to AOD-9604's legal status in California, covering FDA scheduling, the 503A/503B compounding framework, state pharmacy board rules, and what a compliant prescription pathway looks like in 2024.
A guide to AOD-9604's federal regulatory status, Louisiana-specific pharmacy law, compounding pathways under 503A/503B, and what patients need to do to access the peptide legally in 2024.
A detailed breakdown of AOD-9604's federal and Massachusetts legal status, how the FDA bulk compounding list affects access, and what patients need to know before seeking a prescription in 2024.
A breakdown of BPC-157's federal regulatory status, Alabama pharmacy law, and the only legal access paths available to Alabama residents in 2024.
BPC-157 occupies a legal gray zone in Alabama. Learn what FDA policy, 503A/503B compounding rules, and Alabama pharmacy law actually say about obtaining BPC-157 in 2024.
A guide to BPC-157's federal and Florida legal status, the FDA bulks list, 503A/503B compounding rules, and how to get a legitimate prescription in 2024.
A complete breakdown of BPC-157's legal status in Kentucky, covering FDA scheduling, the 503A/503B compounding framework, the Kentucky Board of Pharmacy rules, and what patients and clinicians need to know before obtaining or prescribing BPC-157 in 2024.
A detailed breakdown of BPC-157's federal and Washington State legal status, including FDA regulatory classification, 503A/503B compounding rules, and what patients and clinicians need to know in 2024.
A guide to the federal and North Carolina legal status of PT-141 (Bremelanotide), how to get a legal prescription, and what compounding rules apply in 2024.
A guide to the federal and Texas-specific legal status of PT-141 (Bremelanotide), how to obtain a lawful prescription, and what compounding rules apply in 2024.
A guide to the federal and Virginia-specific legal status of PT-141 (Bremelanotide), including how to obtain a legal prescription and what compounding rules apply in 2024.
A guide to the federal and California legal framework for Egrifta (tesamorelin): FDA approval status, 503A/503B compounding rules, how to get a valid prescription, and what telehealth patients need to know in 2024.
A complete guide to the federal and Oregon-specific legal status of Egrifta (Tesamorelin), how to get a prescription, and what patients and clinicians need to know in 2024.